December 27th 2021
This year’s most-read articles on Fabry disease touched on advancements in therapy, health risks of the disease, and keys to improved diagnosis.
November 29th 2021
November 27th 2021
Study Suggests Improved Screening Strategies for Fabry DiseaseOctober 29th 2021
Early diagnosis of Fabry disease is essential and that since symptoms depend on the type of disease and sex and age of the patient, a high-risk screening system should account for the age of the target population, the researchers said.
Most Patients With Fabry Disease Face Mild or Moderate Symptoms Upon COVID-19 InfectionApril 23rd 2021
Despite concerns that patients with Fabry disease might be at heightened risk of severe symptoms from SARS-CoV-2, early data find that most patients experience mild or moderate symptoms.
Omalizumab Enables Fabrazyme Desensitization After Anaphylaxis, Report SaysApril 15th 2021
This is a case study of a male patient with Fabry disease who presented with severe anaphylaxis following re-initiation of full-strength treatment with intravenous agalsidase beta (Fabrazyme).
Gene Therapy for Fabry Disease to Advance to Phase 2 Clinical TrialsFebruary 4th 2018
Biotechnology company Avrobio has completed a $60 million Series B financing to advance multiple gene therapies, including AVR-RD-01, a proposed single-dose lentiviral gene therapy for Fabry disease (FD).